

glucocorticoid receptor signalling; and/or dyslipidemia, a metabolic disease, inflammation, or a neurodegenerative disease, in a subject.

[0009] In one aspect, provided are compounds having the structure of Formula I:



or a pharmaceutically acceptable salt thereof, wherein $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8 membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and **n** is zero, one, two, three, four, five, or six.

[0010] In one example, provided are compounds having the structure of Formula I:




(I)

or a pharmaceutically acceptable salt thereof, wherein $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is


further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and **n** is zero, one, two, three, four, or five.

[0011] In another example, provided are linker-payload compounds having the structure of Formula II:



or a pharmaceutically acceptable salt thereof, wherein **L** is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or hetereoalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and **n** is zero, one, two, three, four, five, or six.

[0012] In another example, provided are linker-payloads having the structure of Formula II:




(II)

or a pharmaceutically acceptable salt thereof, wherein **L** is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or hetereoalkylene is further bonded to $\mathbf{R^3}$ to


form a 4-, 5-, or 6-membered heterocyclyl; **R²** is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R²** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 4-, 5-, or 6-membered heterocyclyl; **R³** is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R³** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^1a** or **R²** to form the 4-, 5-, or 6-membered heterocyclyl; **R⁴** is hydrogen or alkyl; **R⁵** is oxygen, N**R⁶**, or sulfur; **R⁶** is hydrogen or alkyl; **D*** is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and **n** is zero, one, two, three, four, five, or six.

[0013] In another aspect, provided are compounds having the structure of Formula III:




wherein **L** is a linker; **BA** is a binding agent; **R^1a** and **R^1b** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^1a** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; **R²** is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R²** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 4-, 5-, or 6-membered heterocyclyl; **R³** is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R³** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^1a** or **R²** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; **R⁴** is hydrogen or alkyl; **R⁵** is oxygen, N**R⁶**, or sulfur; **R⁶** is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0014] In another aspect, provided are compounds having the structure of Formula III:




wherein **L** is a linker; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0014a] In another aspect, the present disclosure refers to a compound having the following structure




wherein



L is a linker comprising ; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising

hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0015] In another example, provided are compounds having the structure of Formula III:




wherein **L** is a linker comprising PAB or PABC; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0016] In another aspect, provided are compunds having the structure of Formula III:


hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0015] In another example, provided are compounds having the structure of Formula III:




wherein **L** is a linker comprising PAB or PABC; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0016] In another aspect, provided are compunds having the structure of Formula III:



wherein **L** is a linker; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; wherein conjugation of **L** to **BA** is selected from the group consisting of a click chemistry residue, an amide residue, and a residue comprising two cysteine residues of a single **BA** that are chemically bonded to **L**; and **k** is an integer from one to thirty.

[0017] In another example, provided are compounds having the structure of Formula III:



(III)

wherein **L** is a linker; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene,

wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0018] In another example, provided are methods for treating a disease, disorder, or condition associated with glucocorticoid receptor signaling in a subject comprising administering to the subject an effective amount of a compound, linker-payload, antibody-drug conjugate, pharmaceutical composition, and/or combinations thereof, as described herein.

[0019] In another example, provided are methods for treating dyslipidemia, a metabolic disease, inflammation, or a neurodegenerative disease in a subject comprising administering to the subject an effective amount of a compound, linker-payload, antibody-drug conjugate, pharmaceutical composition, and/or combinations thereof, as described herein.

[0020] In another example, provided are methods for treating dyslipidemia in a subject comprising administering to the subject an effective amount of a compound, linker-payload, antibody-drug conjugate, pharmaceutical composition, and/or combinations thereof, as described herein.

[0021] In another example, provided are methods for treating a metabolic disease in a subject comprising administering to the subject an effective amount of a compound, linker-payload, antibody-drug conjugate, pharmaceutical composition, and/or combinations thereof, as described herein.

[0022] In another example, provided are methods for treating inflammation in a subject comprising administering to the subject an effective amount of a compound, linker-payload, antibody-drug conjugate, pharmaceutical composition, and/or combinations thereof, as described herein.

[0023] In another example, provided are methods for treating a neurodegenerative disease in a subject comprising administering to the subject an effective amount of a compound, linker-payload, antibody-drug conjugate, pharmaceutical composition, and/or combinations thereof, as described herein.

[0023a] In another aspect, the present disclosure refers to an antibody-drug conjugate comprising an antibody, or an antigen binding fragment thereof, where said antibody or antigen binding fragment thereof is conjugated to a compound as disclosed herein.

[0023b] In another aspect, the present disclosure refers to a pharmaceutical composition comprising the compound as disclosed herein, and a pharmaceutically acceptable excipient, carrier, or diluent.

[0023c] In another aspect, the present disclosure refers to compound as disclosed herein or the pharmaceutical composition as disclosed herein for use in therapy.

[0023d] In another aspect, the present disclosure refers to a use of compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating a disease, disorder, or condition associated with glucocorticoid receptor signaling in a subject comprising that the compound is to be administered to the subject.

[0023e] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating dyslipidemia, a metabolic disease, inflammation, or a neurodegenerative disease in a subject.

[0023f] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating dyslipidemia in a subject.


[0023g] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating a metabolic disease in a subject.

[0023h] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating in a subject.


[0023i] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating a neurodegenerative disease in a subject.

[0023j] In another aspect, the present disclosure refers to a method of preparing an antibody-drug conjugate comprising contacting a binding agent with a compound as disclosed herein.


[0023k] In another aspect, the present disclosure refers to a compound selected from the group consisting of




Q1L1-PI;




Q2L1-PII-1;




Q1L1-PII-2;




Q1L1-PII-3;




Q1L1-PII-4;




Q1L1-PII-5;




Q1L1-PII-6;




Q1L1-PII-7;




Q1L1-PII-8;




Q1L1-PII-9;




Q2L3-PIII-1;




Q1L5-PIII-1;




Q1L1-PII-1;




Q1L1-PIII-4;







Q2L6-PII-9;




Q2L7-PII-1;




Q1L1-PII-11;




Q1L1-PII-12;




Q1L6-PII-9;




Q1L7-PII-1;




Q1L15-PII-1;




Q1L17-PII-1;





Q1L6-PII-13;





Q1L13-PIII-1; and






Q1L1-PIV.

WHAT IS CLAIMED IS:

1. A compound having the following structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^2 is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^2** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^3 is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^3** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^2** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^4 is hydrogen or alkyl;

R^5 is oxygen, N**R^6**, or sulfur;

R^6 is hydrogen or alkyl;

D* is a residue of a biologically active compound comprising hydroxyl, amino, or thiol;

n is zero, one, two, three, four, five, or six; and


k is an integer from one to thirty.

2. The compound of claim 1, wherein **D*** is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol.

3. The compound of claim 2, wherein the anti-inflammatory biologically active compound is a steroid or a residue thereof.

4. The compound of claim 2, wherein the anti-inflammatory biologically active compound is an LXR agonist or a residue thereof.

5. A compound having the following structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^2 is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^2** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^3 is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^3** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^2** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^4 is hydrogen or alkyl;

R^5 is oxygen, N**R^6**, or sulfur;

R^6 is hydrogen or alkyl;


D* is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol;

n is zero, one, two, three, four, five, or six; and


k is an integer from one to thirty.

6. The compound of claim 5, wherein **D*** is a residue of a steroid comprising hydroxyl, amino, or thiol.

7. A compound having the following structure



wherein

L is a linker comprising  ;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^2 is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^2** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^3 is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^3** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^2** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^4 is hydrogen or alkyl;


R^5 is oxygen, N**R^6**, or sulfur;

R^6 is hydrogen or alkyl;


D* is a residue of a biologically active compound comprising hydroxyl, amino, or thiol;

n is zero, one, two, three, four, five, or six; and

k is an integer from one to thirty.

8. The compound of claim 7, wherein **L** is a linker comprising , and $\mathbf{R^2}$ is hydrogen.

9. A compound having the following structure

 wherein

L is a linker;

BA is a binding agent;

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

$\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl;

$\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

$\mathbf{R^4}$ is hydrogen or alkyl;

$\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur;

$\mathbf{R^6}$ is hydrogen or alkyl;


D* is a residue of a biologically active compound comprising hydroxyl, amino, or thiol;

n is zero, one, two, three, four, five, or six;

wherein conjugation of **L** to **BA** is selected from the group consisting of a click chemistry residue, an amide residue, and a residue comprising two cysteine residues of a single **BA** that are chemically bonded to **L**; and

k is an integer from one to thirty.

10. The compound of claim 1, having the following structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^2 is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^2** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^3 is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^3** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^2** to form the 4-, 5-, or 6-membered heterocyclyl;

R^4 is hydrogen or alkyl;

R^5 is oxygen, N**R^6**, or sulfur;


R^6 is hydrogen or alkyl;

D* is a residue of a biologically active compound comprising hydroxyl, amino, or thiol;

n is zero, one, two, three, four, five, or six; and

k is an integer from one to thirty.

11. The compound of claim 10 having the structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when **R^{1a}** is alkylene, the alkylene is further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R^{2} is hydrogen or an amino acid side chain;


R^{3} is hydrogen, alkyl, or alkylene, wherein when **R^{3}** is alkylene, the alkylene is further bonded to **R^{1a}** to form the 4-, 5-, or 6-membered heterocyclyl;

D* is a residue of a biologically active compound comprising hydroxyl;

n is zero, one, two, three, four, five, or six; and

k is an integer from one to thirty.

12. The compound of claim 10 having the following structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when **R^{1a}** is alkylene, the alkylene is further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R^{2} is hydrogen or an amino acid side chain;


R^3 is hydrogen, alkyl, or alkylene, wherein when **R^3** is alkylene, the alkylene is further bonded to **R^{1a}** to form the 4-, 5-, or 6-membered heterocyclyl;

D* is a residue of a biologically active compound comprising hydroxyl;

n is zero, one, two, three, four, five, or six; and


k is an integer from one to thirty.

13. The compound of any one of claims 1-12, wherein the linker comprises



.

14. The compound of claim 10, wherein the compound is



wherein

SP^1 and **SP^2**, when present, are spacer groups wherein **SP^1** further comprises a moiety reactive with an antibody or an antigen binding fragment thereof;


each **AA** is an amino acid; and


p is an integer from 1 to 10.


15. The compound of claim 14, wherein **SP^1** comprises a reactive group that comprises an alkyne.


16. The compound of claim 15, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction.

17. The compound of claim 16, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with the binding agent, wherein the binding agent is an azido-functionalized binding agent.

18. The compound of claim 14, wherein **SP²** comprises .

19. The compound of claim 14, wherein **SP²** comprises , and **R²** is hydrogen or alkyl.

20. The compound of claim 17, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with the binding agent, the binding agent is an azido-functionalized binding agent, and **SP²** comprises .

21. The compound of claim 17, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with the binding agent, the binding agent is an azido-functionalized binding agent, **SP²** comprises , and **R²** is hydrogen or alkyl.

22. The compound of claim 14, wherein the binding agent is an antibody modified with a primary amine compound according to the Formula H_2N-**LL**-**X**, wherein **LL** is a divalent linker selected from the group consisting of
a divalent polyethylene glycol (PEG) group;

–$(CH_2)_{\mathbf{n}}$–;

–$(CH_2CH_2O)_{\mathbf{n}}$-$(CH_2)_p$–;

–$(CH_2)_{\mathbf{n}}$-N(H)C(O)-$(CH_2)_{\mathbf{m}}$–;

–$(CH_2CH_2O)_{\mathbf{n}}$-N(H)C(O)-$(CH_2CH_2O)_{\mathbf{m}}$-$(CH_2)_{\mathbf{p}}$–;

–$(CH_2)_{\mathbf{n}}$-C(O)N(H)-$(CH_2)_{\mathbf{m}}$–;

–$(CH_2CH_2O)_{\mathbf{n}}$-C(O)N(H)-$(CH_2CH_2O)_{\mathbf{m}}$-$(CH_2)_{\mathbf{p}}$–;

–$(CH_2)_{\mathbf{n}}$-N(H)C(O)-$(CH_2CH_2O)_{\mathbf{m}}$-$(CH_2)_{\mathbf{p}}$–;

–$(CH_2CH_2O)_{\mathbf{n}}$-N(H)C(O)-$(CH_2)_{\mathbf{m}}$–;

–$(CH_2)_{\mathbf{n}}$-C(O)N(H)-$(CH_2CH_2O)_{\mathbf{m}}$-$(CH_2)_{\mathbf{p}}$–; and


–$(CH_2CH_2O)_{\mathbf{n}}$-C(O)N(H)-$(CH_2)_{\mathbf{m}}$–,





wherein

n is an integer selected from 1 to 12;


m is an integer selected from 0 to 12;

p is an integer selected from 0 to 2; and


X is selected from the group consisting of –SH, $–N_3$, –C≡CH, –C(O)H, tetrazole, ,

, , , and .


23. The compound of claim 22, wherein the binding agent is an antibody modified with a primary amine having the following structure

.


24. The compound of claim 23, wherein the compound is selected from the group consisting of


BA
k


;


BA
k


;


BA
k


;


BA
k


;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;


BA
k


;


BA
k


;


BA
k


;


BA
k


;




;




;




;




;


BA
k


;


BA
k


;


BA
k


;


BA
k


;


BA
k


;




;




;




;


BA
H
N
O
O
O
N
N
N
O
O
N
H
N
H
O
O
O
O
H
H
H
O
O
H
OH
O


k;


BA
H
N
O
O
O
N
N
N
O
O
N
H
N
H
O
O
O
O
H
H
H
O
O
H
OH
O


k;


BA
H
N
O
O
O
O
N
N
N
N
O
O
H
N
O
H
N
O
H
N
O
H
N
O
O
HO
H
H
HO
F
O
k


;


BA
N
H
O
O
O
N
N
N
N
O
H
N
O
H
N
O
H
N
O
H
N
O
O
HO
H
H
HO
F
O
k


;




;




;







;



BA
NH
O
N
N
N
H
O
HO
NH2
OH
k


;



BA
H
N
O
N
N
N
H
O
HO
NH2
OH
k


;
































;




;




;




;





;





;


BA
N
H
O
N
N
N
O
O
NH
O
O
O
O
O
O
O
O
H
H
H
O
O
O
O
H
N
H
O
O
O
H
OH
k



BA
N
H
O
O
N
N
N
O
O
NH
O
O
O
O
O
O
O
O
H
H
H
O
O
O
O
H
N
H
O
O
O
H
OH
k


BA
H
N
O
O
O
O
N
N
N
O
N
O
HN
O
O
O
O
O
O
H
H
H
O
O
O
H
O
N
H
N
O
O
O
O
OH
k;



BA
N
H
O
O
O
N
N
N
O
N
O
HN
O
O
O
O
O
O
H
H
H
O
O
O
H
O
N
H
N
O
O
O
O
OH
k;




;




;




;





;




;












;


BA
H
N
O
O
O
O
N
N
N
O
O
H
N
O
O
H
N
O
O
H
N
O
O
H
N
O
O
O
H
H
H
F
F
O
O
O
OH
k


;


BA
H
N
O
O
O
N
N
N
N
O
O
O
H
N
O
O
O
O
O
O
O
O
O
H
N
O
O
H
N
O
O
H
N
O
O
NH
O
NH2
OH
O
H
N
O
O
H
N
O
O
H
N
O
O
H
H
H
k


;



;




;




;

wherein **k** is 1, 2, 3, or 4.


25. The compound of claim 1, wherein the compound is selected from the group consisting of




,




,




,




,




, and







,



,



, and



; wherein **z** is 1, 2, 3, or 4.

26. The compound of claim 10, wherein **BA** is an antibody or antigen-binding fragment thereof.

27. The compound of claim 26, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof comprising at least one glutamine residue used for conjugation.


28. The compound of claim 26, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof comprising at least two glutamine residues used for conjugation.

29. The compound of claim 26, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof comprising at least four glutamine residues used for conjugation.

30. The compound of claim 29, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof, wherein conjugation is at two Q295 residues; and **k** is 2.

31. The compound of claim 29, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof, wherein conjugation is at two Q295 residues and two N297Q residues; and **k** is 4.

32. A compound having the following structure



or a pharmaceutically acceptable salt thereof, wherein

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^2 is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^2** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R³ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R³** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^1a** or **R²** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R⁴ is hydrogen or alkyl;


R⁵ is oxygen, N**R⁶**, or sulfur;

R⁶ is hydrogen or alkyl;

D* is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and

n is zero, one, two, three, four, five, or six.

33. The compound of claim 32, having the following structure



or a pharmaceutically acceptable salt thereof, wherein

R^1a and **R^1b** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^1a** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 4-, 5-, or 6-membered heterocyclyl;

R² is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R²** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 4-, 5-, or 6-membered heterocyclyl;

R³ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R³** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^1a** or **R²** to form the 4-, 5-, or 6-membered heterocyclyl;

R⁴ is hydrogen or alkyl;


R⁵ is oxygen, N**R⁶**, or sulfur;

R⁶ is hydrogen or alkyl;

D* is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and

n is zero, one, two, three, four, or five.

34. The compound of claim 33 having the following structure



or a pharmaceutically acceptable salt thereof, wherein

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when $\mathbf{R^{1a}}$ is alkylene, the alkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl;


$\mathbf{R^2}$ is hydrogen or an amino acid side chain;

$\mathbf{R^3}$ is hydrogen, alkyl, or alkylene, wherein when $\mathbf{R^3}$ is alkylene, the alkylene is further bonded to $\mathbf{R^{1a}}$ to form the 4-, 5-, or 6-membered heterocyclyl;

D* is acyl, or a residue of a biologically active compound comprising hydroxyl; and

n is zero, one, two, three, four, or five.

35. The compound of claim 33, wherein the compound has the following structure



.


36. The compound of one of claims 32-35, wherein $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are each hydrogen.

37. The compound of any one of claims 32-36, wherein **n** is two.


38. The compound of any one of claims 32-37, wherein **n** is two and $\mathbf{R^2}$ is hydrogen or methyl.

39. The compound of any one of claims 32-38, wherein **n** is two, $\mathbf{R^2}$ is hydrogen or methyl, $\mathbf{R^3}$ is hydrogen, and **D*** is a residue of a biologically active compound comprising hydroxyl.


40. The compound of claim 39, wherein the compound is selected from the group consisting of:



,



, and



; or

a pharmaceutically acceptable salt thereof.


41. The compound of claim 36, wherein **n** is one.


42. The compound of claim 41, wherein $\mathbf{R^2}$ is hydrogen, methyl, or $–CH_2Ph$.


43. The compound of claim 42, wherein $\mathbf{R^3}$ is hydrogen.


44. The compound of claim 43, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.


45. The compound of claim 44, wherein the compound is selected from the group consisting of:



,



,


,


,


,


, and


; or


a pharmaceutically acceptable salt thereof.


46. The compound of claim 41, wherein **R²** is hydrogen or methyl.

47. The compound of claim 46, wherein **R³** is alkyl.

48. The compound of claim 47, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

49. The compound of claim 48, wherein the compound is selected from the group consisting of



and


, or a pharmaceutically acceptable salt thereof.

50. The compound of claim 33, wherein **R^1a** is alkyl or arylalkyl, and **R^1b** is hydrogen.



51. The compound of claim 50, wherein **n** is one.

52. The compound of claim 51, wherein **R²** is hydrogen.

53. The compound of claim 52, wherein **R³** is hydrogen.

54. The compound of claim 53, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

55. The compound of claim 54, wherein the compound is selected from the group consisting of

 and  ; or a pharmaceutically acceptable salt thereof.




56. The compound of claim 33, wherein $\mathbf{R^{1a}}$ is alkylene, where the alkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl;
$\mathbf{R^{1b}}$ is hydrogen; and
$\mathbf{R^3}$ is alkylene further bonded to $\mathbf{R^{1a}}$ to form the 4-, 5-, or 6-membered heterocyclyl.

57. The compound of claim 56, wherein **n** is one.


58. The compound of claim 57, wherein $\mathbf{R^2}$ is hydrogen.



59. The compound of claim 58, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

60. The compound of claim 59, wherein the compound is selected from the group consisting of


, 
, and 
; or a pharmaceutically acceptable salt thereof.

61. The compound of claim 41, wherein the compound is


.


62. The compound of claim 36, wherein the compound is selected from the group consisting of 
and 
.

63. The compound of claim 41, wherein $\mathbf{R^2}$ is alkylene, wherein the alkylene is further bonded to $\mathbf{R^3}$ to form a 6-membered heterocyclyl; and

$\mathbf{R^3}$ is alkylene, wherein the alkylene is further bonded to $\mathbf{R^2}$ to form the 6-membered heterocyclyl.


64. The compound of claim 63, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

65. The compound of claim 64, wherein the compound is



; or a pharmaceutically acceptable salt thereof.

66. A compound having the following structure



or a pharmaceutically acceptable salt thereof, wherein

L is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof;

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or hetereoalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

$\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl;

$\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

$\mathbf{R^4}$ is hydrogen or alkyl;

$\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur;

$\mathbf{R^6}$ is hydrogen or alkyl;

D* is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and


n is zero, one, two, three, four, five, or six.

67. The compound of claim 66, wherein when **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol, then the biologically active compound or residue thereof is an anti-inflammatory biologically active compound or residue thereof.

68. The compound of claim 67, wherein the anti-inflammatory biologically active compound is a steroid or a residue thereof.

69. The compound of claim 67, wherein the anti-inflammatory biologically active compound is an LXR agonist or a residue thereof.

70. The compound of claim 66, having the following structure



or a pharmaceutically acceptable salt thereof, wherein

L is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or hetereoalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^2 is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^2** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^3 is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^3** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^2** to form the 4-, 5-, or 6-membered heterocyclyl;

R^4 is hydrogen or alkyl;


R5 is oxygen, N**R6**, or sulfur;

R6 is hydrogen or alkyl;

D* is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and

n is zero, one, two, three, four, five, or six.

71. The compound of claim 70 having the following structure



or a pharmaceutically acceptable salt thereof, wherein

L is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof;

R1a and **R1b** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when **R1a** is alkylene, the alkylene is further bonded to **R3** to form a 4-, 5-, or 6-membered heterocyclyl;


R2 is hydrogen or an amino acid side chain;

R3 is hydrogen, alkyl, or alkylene, wherein when **R3** is alkylene, the alkylene is further bonded to **R1a** to form the 4-, 5-, or 6-membered heterocyclyl;

D* is acyl, or a residue of a biologically active compound comprising hydroxyl; and

n is zero, one, two, three, four, five, or six.

72. The compound of claim 70 having the following structure




or a pharmaceutically acceptable salt thereof, wherein

L is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof;


R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when **R^{1a}** is alkylene, the alkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;
R^2 is hydrogen or an amino acid side chain;
R^3 is hydrogen, alkyl, or alkylene, wherein when **R^3** is alkylene, the alkylene is further bonded to **R^{1a}** to form the 4-, 5-, or 6-membered heterocyclyl;
D* is acyl, or a residue of a biologically active compound comprising hydroxyl; and
n is zero, one, two, three, four, five, or six.

73. The compound of any one of claims 66-72, wherein the linker further comprises



.

74. The compound of claim 70, wherein the compound is





or a pharmaceutically acceptable salt thereof, wherein
SP^1 and **SP^2**, when present, are spacer groups wherein **SP^1** further comprises a moiety reactive with an antibody or an antigen binding fragment thereof;
each **AA** is an amino acid; and
p is an integer from 1 to 10.


75. The compound of claim 74, wherein **SP^1** comprises a reactive group that comprises an alkyne.


76. The compound of claim 75, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction.

77. The compound of claim 66, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with an azide to form regioisomeric 1,2,3-triazolyl moieties, wherein the azide comprises an azido-functionalized binding agent.

78. The compound of claim 74, wherein **SP²** comprises .

79. The compound of claim 74, wherein **SP²** comprises , and **R²** is hydrogen or alkyl.

80. The compound of claim 77, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with an azide to form regioisomeric 1,2,3-triazolyl moieties, the azide comprises an azido-functionalized binding agent, and **SP²** comprises .

81. The compound of claim 77, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with an azide to form regioisomeric 1,2,3-triazolyl moieties, the azide comprises an azido-functionalized binding agent, **SP²** comprises , and **R²** is hydrogen or alkyl.

82. The compound of claim 74, wherein

R^1a and **R^1b** are hydrogen;


R^2 is hydrogen or methyl;

R^3 is hydrogen; and


n is two.

83. The compound of claim 82, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.


84. The compound of claim 83, selected from the group consisting of



;



; and



; or

a pharmaceutically acceptable salt thereof.

85. The compound of claim 74, wherein

R^{1a} and **R^{1b}** are hydrogen;


R² is hydrogen, methyl, or –CH_2Ph;

R³ is hydrogen or alkyl; and


n is one.

86. The compound of claim 85, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.


87. The compound of claim 86, selected from the group consisting of




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;



;



; and



; or a pharmaceutically acceptable salt thereof.

88. The compound of claim 74, wherein

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are hydrogen;


$\mathbf{R^{2}}$ is hydrogen;

$\mathbf{R^{3}}$ is alkyl; and

n is one.

89. The compound of claim 88, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

90. The compound of claim 89 having a structure



; or a pharmaceutically acceptable salt thereof.

91. The compound of claim 74, wherein

$\mathbf{R^{1a}}$ is alkyl or arylalkyl;

$\mathbf{R^{1b}}$ is hydrogen;


$\mathbf{R^{2}}$ is hydrogen;

$\mathbf{R^{3}}$ is hydrogen; and


n is one.

92. The compound of claim 91, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

93. The compound of claim 92, selected from the group consisting of



; and



; or

a pharmaceutically acceptable salt thereof.

94. The compound of claim 74, wherein

$\mathbf{R^{1a}}$ is alkylene, further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl;

$\mathbf{R^{1b}}$ is hydrogen;


$\mathbf{R^2}$ is hydrogen;

$\mathbf{R^3}$ is alkylene further bonded to $\mathbf{R^{1a}}$ to form the 4-, 5-, or 6-membered heterocyclyl; and


n is one.

95. The compound of claim 94, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

96. The compound of claim 95, selected from the group consisting of




; and



; or

a pharmaceutically acceptable salt thereof.

97. The compound of claim 95, having the structure



or a pharmaceutically acceptable salt thereof.

98. The compound of claim 70, wherein

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are hydrogen;


$\mathbf{R^{2}}$ is hydrogen;

$\mathbf{R^{3}}$ is hydrogen; and

n is one.

99. The compound of claim 98, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

100. The compound of claim 99, having the following structure



or

a pharmaceutically acceptable salt thereof.

101. The compound of claim 70, wherein

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are hydrogen;


$\mathbf{R^{2}}$ is hydrogen or $–CH_2Ph$;

$\mathbf{R^{3}}$ is hydrogen; and


n is four.

102. The compound of claim 101, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.


103. The compound of claim 102, selected from the group consisting of



;



; and



; or a pharmaceutically acceptable salt thereof.

104. The compound of claim 72, wherein


$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are hydrogen;

$\mathbf{R^{3}}$ is hydrogen; and


n is zero.

105. The compound of claim 104, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

106. The compound of claim 105, selected from the group consisting of



and



; or a pharmaceutically acceptable salt thereof.

107. The compound of claim 88, wherein

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are hydrogen;

$\mathbf{R^{2}}$ is hydrogen;


$\mathbf{R^{3}}$ is alkyl;

$\mathbf{R^{4}}$ is alkyl; and

n is one.

108. The compound of claim 107, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

109. The compound of claim 108, having the following structure



; or a pharmaceutically acceptable salt thereof.

110. The compound of claim 70, wherein

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are hydrogen;


$\mathbf{R^{2}}$ is hydrogen or $–CH_2OH$;

$\mathbf{R^{3}}$ is hydrogen; and

n is six.

111. The compound of claim 110, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

112. The compound of claim 111, having the following structure



or a pharmaceutically acceptable salt thereof.

113. The compound of claim 74, wherein

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are hydrogen;


$\mathbf{R^{2}}$ is alkylene, wherein the alkylene is further bonded to $\mathbf{R^{3}}$ to form a 6-membered heterocyclyl;

$\mathbf{R^{3}}$ is alkylene, wherein the alkylene is further bonded to $\mathbf{R^{2}}$ to form the 6-membered heterocyclyl; and

n is one.


114. The compound of claim 113, wherein **D*** is a residue of a biologically active compound comprising hydroxyl.

115. The compound of claim 114, wherein the compound is




; or a pharmaceutically acceptable salt thereof.

116. The compound of claim 84, wherein the compound is




or a pharmaceutically acceptable salt thereof.

117. The compound of claim 84, wherein the compound is




or a pharmaceutically acceptable salt thereof.

118. The compound of claim 96, wherein the compound is




or a pharmaceutically acceptable salt thereof.

119. The compound of claim 87, wherein the compound is



or a pharmaceutically acceptable salt thereof.


120. The compound of claim 87, wherein the compound is





or a pharmaceutically acceptable salt thereof.


121. An antibody-drug conjugate comprising an antibody, or an antigen binding fragment thereof, where said antibody or antigen binding fragment thereof is conjugated to a compound of claim 32 or 66.


122. The antibody-drug conjugate of claim 121, wherein the BA-L is bonded to a moiety selected from the group consisting of



;



;



;



;



;



;



;



;



;



;



;



;



;



;


;



;


;



;



;



; and



.

123. An antibody-drug conjugate comprising an antibody, or an antigen binding fragment thereof, where said antibody or antigen binding fragment thereof is conjugated to a compound of claim 33 or 70.

124. A pharmaceutical composition comprising the compound of any one of claims 1-120, and a pharmaceutically acceptable excipient, carrier, or diluent.

125. The compound of any one of claims 1-120 or the pharmaceutical composition of claim 124 for use in therapy.

126. Use of the compound of any one of claims 1-120 or the pharmaceutical composition of claim 124 in the manufacture of a medicament for treating a disease, disorder, or condition associated with glucocorticoid receptor signaling in a subject comprising that the compound is to be administered to the subject.

127. The use of claim 126, wherein the disease, disorder, or condition, is an inflammatory disease, disorder, or condition.

128. The use of claim 126 or 127, wherein side effects associated with administration of the unconjugated steroid payload of said compound are reduced.

129. Use of the compound of any one of claims 1-120 or the pharmaceutical composition of claim 124 in the manufacture of a medicament for treating dyslipidemia, a metabolic disease, inflammation, or a neurodegenerative disease in a subject.

130. Use of the compound of any one of claims 1-120 or the pharmaceutical composition of claim 124 in the manufacture of a medicament for treating dyslipidemia in a subject.


131. Use of the compound of any one of claims 1-120 or the pharmaceutical composition of claim 124 in the manufacture of a medicament for treating a metabolic disease.

132. Use of the compound of any one of claims 1-120 or the pharmaceutical composition of claim 124 in the manufacture of a medicament for treating inflammation in a subject.

133. Use of the compound of any one of claims 1-120 or the pharmaceutical composition of claim 124 in the manufacture of a medicament for treating a neurodegenerative disease in a subject.


134. A method of preparing an antibody-drug conjugate comprising contacting a binding agent with a compound of claim 70.

135. The compound of claim 33, having the following structure




or a pharmaceutically acceptable salt thereof.

136. The compound of claim 33, having the following structure




or a pharmaceutically acceptable salt thereof.

137. The compound of claim 33, having the following structure




or a pharmaceutically acceptable salt thereof.

138. The compound of claim 33, having the following structure




or a pharmaceutically acceptable salt thereof.

139. The compound of claim 70, having the following structure




or a pharmaceutically acceptable salt thereof.

140. The compound of claim 70, having the following structure




or a pharmaceutically acceptable salt thereof.

141. The compound of claim 70, having the following structure




or a pharmaceutically acceptable salt thereof.

142. The compound of claim 70, having the following structure




or a pharmaceutically acceptable salt thereof.


143. The compound of claim 10, having the following structure




144. The compound of claim 10, having the following structure




145. The compound of claim 10, having the following structure




146. The compound of claim 10, having the following structure




147. The compound of claim 32, selected from the group consisting of




PI;




PII-1;




PII-2;




PII-3;




PII-4;




PII-5;




PII-6;




PII-7;




PII-8;




PII-9;




PII-10;




PIII-1;




PIII-4;




PII-11;




PII-12;



PII-13;




PIII-5; and




PIV.


148. The compound of claim 66, selected from the group consisting of




L1-PI;




L1-PII-1;




L1-PII-2;




L1-PII-3;




L1-PII-4;




L1-PII-5;




L1-PII-6;




L1-PII-7;




L1-PII-8;




L1-PII-9;




L1-PII-10;




L1-PIII-1;




L2-PIII-1;




L3-PIII-1;




L4-PIII-1;




L5-PIII-1;




L1-PIII-4;




L6-PII-9;




L7-PII-1;




L4-PI;




L1-PII-11;




L1-PII-12;




L8-PII-1;




L9-PII-1;




L10-PII-1;




L11-PII-2;




L12-PII-2;




L13-PII-1;




L14-PII-1;




L15-PII-1;




L16-PII-1;




L17-PII-1;




L6-PII-13;




L18-PII-1;




L19-PIII-1;




L9-PIII-1;




L12-PIII-5;



L13-PIII-1;





L1-PIV; and




L14-PIV.

149. A compound selected from the group consisting of







Q1L1-PI;




Q2L1-PII-1;







Q1L1-PII-2;




Q1L1-PII-3;




Q1L1-PII-4;




Q1L1-PII-5;




Q1L1-PII-6;




Q1L1-PII-7;




Q1L1-PII-8;




Q1L1-PII-9;




Q2L3-PIII-1;




Q1L5-PIII-1;




Q1L1-PII-1;




Q1L1-PIII-4;







Q2L6-PII-9;




Q2L7-PII-1;




Q1L1-PII-11;




Q1L1-PII-12;




Q1L6-PII-9;




Q1L7-PII-1;




Q1L15-PII-1;







Q1L17-PII-1;





Q1L6-PII-13;






Q1L13-PIII-1; and







Q1L1-PIV.


150. The compound of claim 1, selected from the group consisting of






BA-L1-PII-1;






BA-L1-PIII-1;




BA-L2-PIII-1;




BA-L3-PIII-1;





BA-L4-PIII-1;







BA-L5-PIII-1;






BA-L14-PII-1;






BA-L6-PII-9;



BA-L13-PII-1; and



BA-L8-PII-1

wherein **BA** is an antibody or an antigen binding fragment thereof; and

k is an integer from one to four.